loader

Silverback Therapeutics Inc.

NASDAQ:SBTX
1 min read

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy®

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

neffy® Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions

Real-World Evidence Supports Clinical Effectiveness of neffy® in Patients Experiencing Anaphylaxis

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

ARS Pharmaceuticals Submits Response for neffy® Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Latest News

More News

Latest News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES